Editorial Commentary: Dasatinib With Quercetin Shows Promise in Decreasing Age-Related Senescence in the Rotator Cuff Tendon-Can It Work Elsewhere?
Abstract:
Cellular senescence is a fundamental mechanism seen in all age-related diseases. Human supraspinatus tendon and adjacent bursal specimens evaluated for cellular senescence by immunohistochemistry and gene expression show more senescent cells in older patients. This confirms the observation that older patients are more likely to have rotator cuff pathology, and older age is associated with lower rates of rotator cuff healing and more frequent tendon retears. Senolytic drugs can selectively eliminate senescent cells without a localized or systemic impact. Tendon and bursal specimens co-cultured and then incubated with dasatinib and quercetin for 48 hours show a significant decrease in senescent cells. This suggests that these drugs may slow biological aging in rotator cuff tendons and offer the possibility of a clinically effective treatment for the aging rotator cuff tendon. Moreover, this concept is promising for the development of future effective therapies addressing tissue senescence.
Insights
Cellular senescence, a hallmark of aging, increases in rotator cuff tendons with age. Senolytic drugs like dasatinib and quercetin effectively reduced these senescent cells, offering potential treatments for age-related tendon dysfunction.
Area of Science:
- Gerontology
- Orthopedics
- Cell Biology
Background:
- Cellular senescence is a key factor in age-related diseases and tissue degeneration.
- Older individuals exhibit increased cellular senescence in supraspinatus tendon and bursal tissues.
- Age-related senescence correlates with higher incidence of rotator cuff pathology and impaired healing.
Discussion:
- Senolytic drugs, such as dasatinib and quercetin, can selectively eliminate senescent cells.
- Treatment with senolytic drugs significantly reduced senescent cell burden in co-cultured tendon and bursal explants.
- This demonstrates a potential therapeutic strategy for mitigating age-related changes in rotator cuff tendons.
Key Insights:
- Increased cellular senescence in rotator cuff tissues is linked to patient age.
- Senescent cells in rotator cuff tendons can be targeted and reduced by senolytic drug combinations.
- Dasatinib and quercetin treatment shows promise in reducing cellular senescence in aged tendon tissues.
Outlook:
- Senolytic therapy may offer a novel approach to treating age-related rotator cuff pathology.
- Further research could explore the clinical efficacy of senolytics for improving rotator cuff healing and function.
- Targeting tissue senescence presents a promising avenue for regenerative medicine in orthopedic conditions.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
01:37Mitochondria
01:19The Effect of Aging on Tissues